COVID-19 is ravaging the world. Collaboration of everyone involved in a trial is required. We hosted a webinar on April 2 to share information and lessons learned by sponsor, site, and CRO. During this webinar, three speakers addressed various aspects of the impacts and mitigation strategies to keep the trial going and to maintain integrity.
Dr. Emil Fu, SVP of FMD presented the CRO perspective and discussed lessons learned of managing clinical trials in China during the height of the epidemic and the quick recovery in the market.
Dr. Armon Sharei, CEO of SQZ Biotech, discussed differential impact on therapeutic areas and the strategies SQZ are taking to protect work force and maintain trial compliance.
Dr. Yu Tang, Deputy Director, GCP Center, Cancer Hospital of China Academy of Medical Sciences discussed the quick responses the hospital took to protect cancer patients and healthcare professional and collaboration across site.
Dr. Simone Fishburn, Editor in Chief of BioCentury, moderated the program. Before joining BioCentury, Dr. Fishburn was a director of translational research at Nektar Therapeutics.